Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension safety study of canakinumab in Japanese patients with periodic fever syndromes
2017-001678-40Phase 3
- Sponsor
- Novartis
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of canakinumab in TNF receptor-associated periodic syndrome (TRAPS), Mevalonate kinase deficiency (MKD), hyperimmunoglobulin D syndrome (HIDS) and 1 more, sponsored by Novartis.
02
Drugs
canakinumab
03
Conditions
TNF receptor-associated periodic syndrome (TRAPS)Mevalonate kinase deficiency (MKD)hyperimmunoglobulin D syndrome (HIDS)Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on 2017-001678-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001678-40.